MERUS N.V. EO -09 (2GH F) stock market data APIs
€57.7385
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
MERUS N.V. EO -09 Financial Data Overview
Price chart is built with
Anychart
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Prev. Close
57.7385
Open
57.7385
High
57.7385
Low
57.7385
52 wk Range
29.4-61
Market Cap
4 387 M
Shares Outstanding
75 634 K
Revenue
56 228 K
EPS
-2.23
Beta
1.19
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MERUS N.V. EO -09 data using free add-ons & libraries
Get MERUS N.V. EO -09 Fundamental Data
MERUS N.V. EO -09 Fundamental data includes:
- Net Revenue: 56 228 K
- EBITDA: -344 534 016
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -1.15
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MERUS N.V. EO -09 News
New
Merus to Present at the 2025 Wells Fargo Healthcare Conference
Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies ...
We Think Merus (NASDAQ:MRUS) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com l...
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies ...
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $2.23 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.81 per share a year ago. These figures are adj...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
